| 4.06 -0.07 (-1.69%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.96  |
1-year : | 6.8 |
| Resists | First : | 5.1 |
Second : | 5.82 |
| Pivot price | 4.42 |
|||
| Supports | First : | 3.93 |
Second : | 3.26 |
| MAs | MA(5) : | 4.21 |
MA(20) : | 4.54 |
| MA(100) : | 4.4 |
MA(250) : | 4.79 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 11.6 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 7.94 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TLSI ] has closed above bottom band by 19.5%. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.33 - 4.36 | 4.36 - 4.38 |
| Low: | 3.86 - 3.89 | 3.89 - 3.92 |
| Close: | 4.01 - 4.06 | 4.06 - 4.1 |
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Wed, 07 Oct 2026
296 shares sold for taxes: TriSalus Life Sciences (TLSI) research chief's sale was not discretionary. - Stock Titan
Wed, 07 Oct 2026
TriSalus Life Sciences (TLSI) regulatory chief sells 316 shares to cover stock-vesting taxes - Stock Titan
Wed, 23 Sep 2026
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance - Yahoo Finance
Wed, 23 Sep 2026
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
Tue, 22 Sep 2026
TriSalus receives FDA clearance for TriNav Advance device - Investing.com
Tue, 22 Sep 2026
Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 62 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 33.9 (%) |
| Held by Institutions | 35.7 (%) |
| Shares Short | 3,350 (K) |
| Shares Short P.Month | 3,690 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | -62.6 % |
| Operating Margin | -86.1 % |
| Return on Assets (ttm) | -36.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.7 % |
| Gross Profit (p.s.) | 0.62 |
| Sales Per Share | 0.73 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.33 |
| PEG Ratio | 0 |
| Price to Book value | 36.9 |
| Price to Sales | 5.54 |
| Price to Cash Flow | -10.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|